A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Part A: Maximum Tolerated Dose (MTD)
研究概览
简要总结
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with metastatic hormone-refractory prostate cancer (HRPC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent
- •Histological or cytological confirmation of prostate cancer
- •Evidence of metastatic disease on CT scan, MRI, or bone scan
- •Surgically or continuously medically castrated with LHRH analogue
- •Progressive disease after most recent therapy
- •Disease progression by CT/MRI
- •Bone scan progression: appearance of 1 or more new lesions since last bone scan
- •Rising PSA
- •World health organization (WHO) performance status 0 to 2
- •Life expectancy of 12 weeks or longer
排除标准
- •Use of anti-hormonal therapies (including ketoconazole, aminoglutethimide, finasteride and anti-androgen therapies) within 4 weeks of starting study treatment, except for bicalutamide and nilutamide which are excluded within 6 weeks of starting study treatment. Estramustine or estrogens, if taken, have to be stopped at least 4 weeks before starting treatment.
- •Definite or suspected personal history or family history of adverse drug reactions, or hypersensitivity to drugs that are endothelin antagonist; history of severe hypersensitivity reactions to drugs formulated with polysorbate
- •Prior cytotoxic chemotherapy for metastatic prostate cancer
- •Radiotherapy within 4 weeks before the start of study therapy
- •Systemic radionuclide therapy (ie strontium chloride Sr89, 186Re-labeled HEDP, or 153Sm-EDTMP pentasodium) within 12 weeks before entering study
- •Use of potent CYP450 inhibitors (such as itraconazole, ritonavir, indinavir, erythromycin, troleandomycin, clarithromycin, diltiazem, verapamil) within 2 weeks before study entry.
- •Use of potent CYP450 inducers (such as phenytoin, rifampicin, carbamazepine and phenobarbitone, St. John's Wort) within 2 weeks before study entry.
- •NOTE: Dexamethasone is a known inducer of CYP2D6 and CYP3A4 but is not considered exclusionary for purposes of this study.
- •New neurologic symptoms or signs consistent with acute or evolving spinal cord compression confirmed by magnetic resonance imaging (MRI) (except for those previously treated and have stable symptoms).
- •History of past or current epilepsy, epilepsy syndrome, or other seizure disorder
- •History of Migraine or chronic headache
- •Symptomatic central nervous system (CNS) metastases
- •Absolute Neutrophil Count (ANC) <1.5 x 109/L (1,5000/mm3)
- •Platelet count < 100 x 109/L (100,000/mm3)
- •Serum bilirubin greater than the upper limit of normal (ULN)
- •Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 1.5 times the upper limit of normal (ULN)
- •Creatinine clearance <50 mL/min
- •QT interval corrected for heart rate by the Barrett Formula (QTc) > 470 msec at screening
- •New York Heart Association (NYHA) class II-IV Heart Disease
- •Myocardial infarction (heart attack) within past 3 months
- •CTCAE grade ≥2 Peripheral Neuropathy
- •Treatment with a non-approved or investigational drug within 30 days before study entry
- •Evidence of any other significant clinical symptoms, abnormal laboratory findings or recent surgery that patients has not recovered from that make it undesirable for the patient to participate in the study in the opinion of the investigator(s)
- •Involvement in the planning and conduct of the study
- •Previous treatment in the present study
研究组 & 干预措施
Part A
Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: ZD4054 (Zibotentan) (Drug)
Part A
Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: Docetaxel (Drug)
Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)
Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: ZD4054 (Zibotentan) (Drug)
Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)
Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: Docetaxel (Drug)
Part B
Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: ZD4054 (Zibotentan) (Drug)
Part B
Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: Docetaxel (Drug)
Part B (placebo)
Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: Docetaxel (Drug)
Part B (placebo)
Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
干预措施: Placebo (Drug)
结局指标
主要结局
Part A: Maximum Tolerated Dose (MTD)
时间窗: Part A: Cycle 1 ('Primary analysis' corresponding to data cut-off 5th March 2008)
次要结局
未报告次要终点